We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

Interchangeability of drugs, not doses

  • Baker & McKenzie
  • -
  • Australia
  • -
  • October 11 2011

An application to declare invalid the placement of two cholesterol lowering drugs in the same therapeutic group was recently rejected by the Federal Court

Anti-bribery and corruption regulation increasing risks for life sciences companies

  • Baker & McKenzie
  • -
  • Australia
  • -
  • October 11 2011

Some recent changes to anti-bribery and corruption laws in a number of jurisdictions, together with current high levels of regulator activity, have increased the compliance risks for both companies and individuals

Transparency Review Report published

  • Baker & McKenzie
  • -
  • Australia
  • -
  • October 11 2011

The Final Report of the Pearce Review to improve the transparency of the Therapeutic Goods Administration (TGA) was released in June 2011

R&D tax offset legislation passed by Parliament

  • Baker & McKenzie
  • -
  • Australia
  • -
  • October 11 2011

Parliament has passed legislation to replace the existing Research and Development (R&D) tax concession with a simplified R&D tax incentive (also known as the R&D tax offsets